Technical Analysis for ONCT - Oncternal Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Bearish Engulfing | Bearish | 0.41% | |
| Fell Below 20 DMA | Bearish | 0.41% | |
| Fell Below 50 DMA | Bearish | 0.41% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.41% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 23 hours ago |
| Rose Above 20 DMA | 1 day ago |
| Rose Above 50 DMA | 1 day ago |
| Up 5% | 1 day ago |
| Up 3% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Oncternal Therapeutics, Inc. Description
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Clinical Development Treatment Of Cancer Monoclonal Antibody Organic Compounds Chemical Compounds Drug Development Sarcoma Hematologic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.0 |
| 52 Week Low | 5.5656 |
| Average Volume | 7,439 |
| 200-Day Moving Average | 7.77 |
| 50-Day Moving Average | 8.78 |
| 20-Day Moving Average | 8.66 |
| 10-Day Moving Average | 8.51 |
| Average True Range | 0.52 |
| RSI (14) | 48.45 |
| ADX | 10.5 |
| +DI | 21.36 |
| -DI | 25.57 |
| Chandelier Exit (Long, 3 ATRs) | 7.93 |
| Chandelier Exit (Short, 3 ATRs) | 9.53 |
| Upper Bollinger Bands | 9.23 |
| Lower Bollinger Band | 8.10 |
| Percent B (%b) | 0.41 |
| BandWidth | 13.06 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0169 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.20 | ||||
| Resistance 3 (R3) | 9.27 | 9.12 | 9.09 | ||
| Resistance 2 (R2) | 9.12 | 8.96 | 9.09 | 9.05 | |
| Resistance 1 (R1) | 8.84 | 8.86 | 8.77 | 8.77 | 9.02 |
| Pivot Point | 8.70 | 8.70 | 8.66 | 8.66 | 8.70 |
| Support 1 (S1) | 8.41 | 8.53 | 8.34 | 8.34 | 8.09 |
| Support 2 (S2) | 8.27 | 8.43 | 8.23 | 8.06 | |
| Support 3 (S3) | 7.99 | 8.27 | 8.02 | ||
| Support 4 (S4) | 7.91 |
